Chemomab Therapeutics Ltd.

Chemomab Therapeutics Ltd. is a clinical-stage biotechnology company focused on developing antibody-based therapies for fibro-inflammatory diseases. Its lead program, nebokitug, is designed to neutralize the soluble protein CCL24 and is being studied for primary sclerosing cholangitis and other immune-fibrotic conditions. The company is headquartered in Tel Aviv, Israel and is publicly listed on Nasdaq in the United States.

9.08

9.08

— Chemomab Therapeutics Ltd.
%
Lead therapeutic program85% Nebokitug and related clinical development activities targeting CCL24-driven fibrosis and inflammation.
Pipeline development10% Preclinical and translational work to expand nebokitug into additional fibro-inflammatory indications.
Partnering and licensing5% Out-licensing, collaboration, and strategic partnership opportunities around the nebokitug asset.

Chemomab does not sell commercial medicines to end patients; its economic counterparties are primarily pharmaceutical...

  • Strategic pharma partnersprimary

    Potential licensees or collaborators that may fund development or commercialize nebokitug in defined territories or indications.

  • Regulatory agenciesprimary

    FDA and other health authorities that review trial design, endpoints, and approval pathways for nebokitug.

  • Clinical trial ecosystemsecondary

    Investigators, hospitals, and trial networks that enroll PSC and other fibro-inflammatory patients into studies.

  • Patients with rare fibro-inflammatory diseaseprimary

    Patients with PSC and related conditions who are the intended beneficiaries of the company’s therapies.

Chemomab is headquartered in Tel Aviv, Israel, while its equity is listed on Nasdaq in the United States...

  • •Headquartered in Tel Aviv, Israel
  • •Nasdaq-listed in the United States
  • •Clinical development is global and trial-driven
  • •Regulatory and partnering activity centers on the U.S. and Israel
  • •Future commercialization would likely depend on partner geography

Chemomab’s strategy centers on advancing nebokitug through late-stage clinical development in PSC and using...

01
Advance PSC clinical developmentshort-term

PSC is the lead indication and the clearest path to value creation for nebokitug.

02
Strengthen translational evidenceshort-term

Biomarker and mechanistic data help support disease-modifying claims and partnering interest.

03
Secure strategic partnershipsmedium-term

A partner can provide capital, development scale, and commercialization reach.

04
Broaden indication scopemedium-term

Additional fibro-inflammatory diseases could expand the asset’s commercial opportunity.

Chemomab’s business depends heavily on the clinical and regulatory success of a single lead asset, so trial outcomes...

critical

Clinical development failure

Nebokitug is the lead asset, so negative efficacy or safety results would materially impair the company.

Scope
PSC Phase 3 and follow-on indications
Materiality
high
high

Regulatory uncertainty

Approval depends on FDA acceptance of endpoints, trial design, and evidence package.

Scope
PSC development pathway
Materiality
high
high

Financing and dilution risk

Clinical-stage biotech companies typically require external capital before commercialization.

Scope
Operating runway and trial funding
Materiality
high
medium

Partnering execution risk

The company is pursuing strategic options that may not close on favorable terms or timing.

Scope
Out-licensing and collaboration discussions
Materiality
medium
medium

Competitive and scientific risk

Other therapies or changing scientific views could reduce the perceived value of CCL24 targeting.

Scope
Fibro-inflammatory disease market
Materiality
medium
Research and development expense
Affects operating loss and period-to-period comparability
Stock-based compensation
Affects reported operating expenses and dilution analysis
Clinical accrual estimates
Can shift expenses between quarters
Collaboration and milestone accounting
Could affect revenue recognition if deals are signed

C4 Therapeutics, Inc.

CCCC · Biological Products, (No Diagnostic Substances)

AMICUS THERAPEUTICS, INC.

Pharmaceutical Preparations

Relay Therapeutics, Inc.

RLAY · Biological Products, (No Diagnostic Substances)

Larimar Therapeutics, Inc.

LRMR · Pharmaceutical Preparations

CAPRICOR THERAPEUTICS, INC.

CAPR · Pharmaceutical Preparations

cbdMD, Inc.

YCBD · Perfumes, Cosmetics & Other Toilet Preparations

: 18.7.2026